Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: Guidance for drug development

HIV Clinical Trials

Volumn 13, Issue 1, 2012, Pages 1-10

  Morris, Bethany ^a   Scott, Callie ^a   Wilkin, Timothy ^d   Sax, Paul ^b,c   Gulick, Roy ^d   Freedberg, Kenneth ^a,c,e   Schackman, Bruce ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ART na ve; HIV; immune enhanced

Indexed keywords

EFAVIRENZ; EMTRICITABINE; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STANDARD; TREATMENT DURATION; UNITED STATES;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DRUG DISCOVERY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS;

EID: 84858259555     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1301-1     Document Type: Article

References (43)

1. Chêne G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. L ancet. 2003;362(9385):679-686. PMID:12957089.
2. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with hiv-1 infection according to immunologic and virologic response after 6 months of highly active anti-retroviral therapy. Ann Intern Med. 2000; 133(6):401-410. PMID:10975957.
3. Zoufaly A, an der Heiden M, Kollan C, et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis. 2011;203(3):364-371. PMID:21208929.
4. Abrams D', Levy Y, Losso MH', et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361(16):1548-1559. PMID:19828532.
5. Wilkin TJ, Lalama C, Tenorio A, et al. Maraviroc (MVC) intensification for supoptimal CD4+ response despite sustained virologic supression: ACTG 5256. In: Program and abstracts of the 17th Conference of Retroviruses and Opportunistic Infections (CROI); February 16-19, 2010; San Francisco, CA, USA. Abstract 285.
6. Hunt P, Shulman N, Hayes T, et al. Immunomodulatory effects of MVC intensification in HIV-infected individuals with incomplete CD4+ T cell recovery during suppressive ART. In: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections (CROI); F ebruary 27-March 2, 2011; Boston, MA, USA. Abstract 153LB.
7. ClinicalTrials.gov. Maraviroc (CCR5) antagonism to decrease the incidence of the Immune Reconstitu-tion Inflammatory Syndrome in HIV-infected patients (CADIRIS). US National Institutes of Health. http://clini-caltrials.gov/ct2/ show/results/NCT00988780. Accessed March 12, 2011.
8. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with ccr5-tropic hiv-1 infection. J infect dis. 2010;201(6): 803-813. PMID:20151839
9. Sierra-Madero J, Di Perri G, Wood R, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials. 2010;11(3):125-132. PMID:20736149.
10. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006; 44(11):990-997. PMID:17063130. (Pubitemid 44674030)
11. Schackman BR, Scott CA, Sax PE, et al. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007;45(8):1062-1070. PMID:17879926. (Pubitemid 47580359)
12. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of hla-b*5701 genetic screening to guide initial antiretroviral therapy for hiv. AIDS. 2008; 22(15):2025-2033. PMID:18784465.
13. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
14. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-356. PMID:18362813.
15. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003; 163(14):1637-1641. PMID:12885677. (Pubitemid 36898950)
16. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-178. PMID:20528406. (Pubitemid 351959547)
17. Schackman BR, Gold HT, Stone PW, Neumann PJ. How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions? Pharmacoeconomics. 2004; 22(5):293-300. PMID:15061679. (Pubitemid 38553700)
18. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the united states. Ann Intern Med. 2009; 151(8):538-545. PMID:19841455.
19. Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the united states. Clin Infect Dis. 2007; 45(Suppl 4):S248-254. PMID:18190295. (Pubitemid 351417225)
20. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946-954. PMID:9182471. (Pubitemid 27255797)
21. Multicenter AIDS Cohort Study (MACS). Public Dataset: Release P04 database on the Internet. Springfield, VA: National Technical Information Service; 1995.
22. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N engl J med. 2001; 344(11):824-831. PMID:11248160. (Pubitemid 32222162)
23. Freedberg KA, Scharfstein JA, Seage GR 3rd, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279(2):130-136. PMID:9440663.
24. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS. 2001;15(1):77-85. PMID:11192871. (Pubitemid 32055782)
25. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. January 10, 2011. Department of Health and Human Services. http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed March 22, 2011.
26. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207. PMID:19357635.
27. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-Dose zidovudine/lamivudine and efavirenz in anti-Retroviral-Naive patients: virologic, immunologic, and morphologic changes-A 96-week analysis. J Acquir Immune Defic Syndr. 2006; 43(5):535-540. PMID:17057609. (Pubitemid 44885619)
28. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260. PMID:16421366. (Pubitemid 43113030)
29. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and effi-cacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369(9569):1261-9. PMID:17434401. (Pubitemid 46553846)
30. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazana-vir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685-694. PMID:15821394. (Pubitemid 40593073)
31. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides n oninferior antiviral activity compared with a twice-daily r egimen. J Acquir Immune Defic Syndr. 2006;43(2):153-160. PMID:16951643. (Pubitemid 44454808)
32. Lalezari J, Goodrich J, DeJesus E, et al, eds. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada Abs: 104bLB. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
33. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40(4):404-412. PMID:16280694. (Pubitemid 41669173)
34. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 hiv-1 infection. N Engl J med. 2008; 359(14):1429-1441. PMID:18832244.
35. Arias E. United States Life Tables, 2004: National Vital Statistics Reports. Centers for Disease Control and Prevention; 2007.
36. Texas Department of State Health Services. Texas vital statistics: life tables. 2005. http://www.dshs.state.tx.us/chs/vstat/annrpts.shtm. Accessed March 22, 2011.
37. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of anti-retroviral therapy. Clin Infect Dis. 2009;49(10):1570-1578. PMID:19845472.
38. Centers for Medicare and Medicaid Services. Medicare Physician Fee Schedule. http://www.cms.hhs.gov/physi-cianfeesched/downloads/RVU08D.zip. Accessed October 3, 2011.
39. Red Book. Montvale, NJ: Thomson Reuters; 2009.
40. Gebo KA, Moore RD, Fleishman JA. The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV. Hopkins HIV Rep. 2003;15(6):5-6. PMID:14974424.
41. University HealthSystems Consortium. CDP online report. 2008. www.uhc.edu. Accessed July 27, 2011.
42. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512-1520. PMID:20415573.
43. Vital signs: HIV testing and diagnosis among adults-United States, 2001-2009. MMWR Morb Mortal Wkly Rep. 2010;59(47):1550-1555. PMID:21124295.